20:52 , May 30, 2019 |  BC Extra  |  Clinical News

May 30 Clinical Quick Takes: Cancer report shows decline in mortality from melanoma; plus Cara, Novartis

Decrease in mortality from melanoma attributed to checkpoint inhibitors  The rate of death due to melanoma of the skin declined by 8.5% per year during 2014-16 among men and 6.3% per year in 2013-16 among...
17:49 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Cara raises $85.5M follow-on

Cara Therapeutics Inc. (NASDAQ:CARA) raised $85.5 million on July 18 through the sale of 4.5 million shares at $19 in a follow-on underwritten by Jefferies, BofA Merrill Lynch, Piper Jaffray, Stifel, Canaccord Genuity, Needham, H.C....
14:53 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Cara's IV analgesic meets in Phase III for postoperative pain

Cara Therapeutics Inc. (NASDAQ:CARA) said IV CR845 met the primary and secondary endpoints in the adaptive Phase II/III CLIN3001 trial to treat postoperative pain in patients undergoing abdominal surgery. On the primary endpoint, the 1...
20:24 , Jun 27, 2018 |  BC Extra  |  Clinical News

Cara gains after analgesic readout

Cara Therapeutics Inc. (NASDAQ:CARA) added $1.62 (10%) to $18.06 Wednesday after IV CR845 met the primary and secondary endpoints in the adaptive Phase II/III CLIN3001 study to treat postoperative pain in patients undergoing abdominal surgery....
18:33 , May 25, 2018 |  BC Week In Review  |  Company News

Vifor Fresenius to commercialize Cara’s Korsuva in international markets

Cara Therapeutics Inc. (NASDAQ:CARA) granted Vifor Fresenius Medical Care Renal Pharma Ltd. rights to commercialize Korsuva difelikefalin (IV CR845) to treat chronic kidney disease-associated pruritus in dialysis patients. Vifor Fresenius acquired worldwide rights, excluding the...
21:30 , May 23, 2018 |  BC Extra  |  Company News

Vifor Fresenius to commercialize Cara’s Korsuva in international markets

Cara Therapeutics Inc. (NASDAQ:CARA) gained $4.96 (43%) to $16.56 on Wednesday after Vifor Fresenius Medical Care Renal Pharma Ltd. acquired rights to commercialize Korsuva difelikefalin (IV CR845) to treat chronic kidney disease-associated pruritus in dialysis...
19:28 , Jan 17, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Structural analyses of active, ligand-bound KOR could guide the design of biased KOR agonists to treat pain. A complex of crystallized KOR and a high-affinity ligand was suspended in a lipid-containing solution...
20:07 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

Cara's oral analgesic misses in Phase IIb

Cara Therapeutics Inc. (NASDAQ:CARA) reported top-line data from the Phase IIb CLIN2002 trial in 476 patients with osteoarthritis (OA) of the hip or knee who were experiencing moderate to severe pain showing that twice-daily 1,...
18:36 , Jul 6, 2017 |  BC Week In Review  |  Clinical News

IDMC recommends continuation of Cara’s Phase III of IV CR845 in postoperative pain

Cara Therapeutics Inc. (NASDAQ:CARA) said an IDMC recommended continuation of the Phase III CLIN3001 trial evaluating 0.5 and 1 μg/kg IV CR845 to treat acute postoperative pain following abdominal surgery. The recommendation was based on...
23:52 , Jun 29, 2017 |  BC Extra  |  Clinical News

Cara's analgesic misses Phase IIb endpoint

Cara Therapeutics Inc. lost $7.09 (28%) to $18.42 in after-hours trading Thursday after it said oral CR845 missed the primary endpoint in the Phase IIb CLIN2002 trial to treat pain in patients with osteoarthritis of...